Provided by Tiger Trade Technology Pte. Ltd.

Protagonist Therapeutics

147.75
+3.422.37%
Pre-market: 147.750.00000.00%06:05 EDT
Volume:567.40K
Turnover:82.97M
Market Cap:9.56B
PE:143.45
High:149.30
Open:143.26
Low:141.95
Close:144.33
52wk High:160.81
52wk Low:54.50
Shares:64.71M
Float Shares:63.17M
Volume Ratio:1.20
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.03
EPS(LYR):-2.0500
ROE:10.98%
ROA:4.55%
PB:11.36
PE(LYR):-72.07

Loading ...

J&J Mastered Cancer Biotech Deals on the Cheap. Can it Stay on the Cutting Edge? -- Heard on the Street -- WSJ

Dow Jones
·
May 28

Genvor names Donald Kalkofen chief financial officer

Reuters
·
May 21

Analysts Offer Insights on Healthcare Companies: Adlai Nortye Ltd. Sponsored ADR (ANL), Protagonist Therapeutics (PTGX) and Nuvalent (NUVL)

TIPRANKS
·
May 14

Protagonist Therapeutics CEO Dinesh Patel disposes of USD 7.51 million common shares

Reuters
·
May 13

Protagonist Therapeutics director Bryan Giraudo disposes 59,130 shares worth $5.92 million

Reuters
·
May 12

Protagonist Therapeutics (PTGX) Receives a Buy from Citi

TIPRANKS
·
May 10

Protagonist Therapeutics Q1 Profit Challenges Trailing Loss Narrative For PTGX Investors

Simply Wall St.
·
May 07

Protagonist Therapeutics price target raised to $110 from $97 at Goldman Sachs

TIPRANKS
·
May 07

Protagonist Therapeutics management to meet virtually with Clear Street

TIPRANKS
·
May 07

Protagonist Therapeutics participates in a conference call with JPMorgan

TIPRANKS
·
May 07

H.C. Wainwright Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

TIPRANKS
·
May 07

Wedbush Adjusts Price Target on Protagonist Therapeutics to $118 From $112, Maintains Outperform Rating

MT Newswires Live
·
May 06

Protagonist Therapeutics Is Maintained at Outperform by Wedbush

Dow Jones
·
May 06

Barclays Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

TIPRANKS
·
May 06

Analysts’ Top Healthcare Picks: Biodesix (BDSX), Protagonist Therapeutics (PTGX)

TIPRANKS
·
May 06

Protagonist Therapeutics Q1 EPS $0.05 Beats $(0.42) Estimate, Sales $56.368M Beat $16.273M Estimate

Benzinga Earnings
·
May 06

Protagonist Therapeutics Q1 revenue doubles on ICOTYDE milestone

Reuters
·
May 06

Protagonist returns to Q1 FY26 profit; revenue rises to $56.37 million

Reuters
·
May 06

BRIEF-Protagonist Therapeutics Q1 EPS USD 0.05

Reuters
·
May 06

Analysts Conflicted on These Healthcare Names: Molina Healthcare (MOH), Design Therapeutics (DSGN) and Protagonist Therapeutics (PTGX)

TIPRANKS
·
Apr 29